Hospital
Providence Health & Services - Washington
Providence Health & Services - Washington was paid $26.79M by Medicaid between Jan 2018 and Dec 2024, across 217 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 15% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES - WASHINGTON
COLVILLE, WA 99114
COLVILLE, WA 99114
33aNPI1003067679assigned 10/01/2008
33bProvider typeCritical Access Hospital
28Total paid$26.79M
24GClaims378,632
24DCodes billed217
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#5 of 30
Median peer was paid$9.10M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,999 | $3.52M | |
| 2019 | 56,466 | $3.50M | |
| 2020 | 46,608 | $3.28M | |
| 2021 | 60,911 | $4.20M | |
| 2022 | 57,734 | $4.67M | |
| 2023 | 56,774 | $3.99M | |
| 2024incomplete | 50,140 | $3.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 2,809 | 2,685 | $4.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 9,683 | 7,012 | $2.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 11,525 | 9,306 | $2.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 14,955 | 12,898 | $2.03M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 1,993 | 1,885 | $813K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 22,621 | 19,459 | $775K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 455 | 440 | $494K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 5,110 | 4,315 | $470K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 11,022 | 4,597 | $467K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 27,316 | 23,869 | $437K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 4,426 | 3,043 | $382K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.3% | 7,841 | 3,343 | $351K |
205 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 5,952 | $348K |
| 80053 | Comprehensive metabolic panel | 1.3% | 22,329 | $340K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 4,182 | $332K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 6,114 | $331K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 5,981 | $284K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 3,242 | $274K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 789 | $259K |
| 73630 | <1% | 1,914 | $250K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,039 | $248K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,197 | $224K |
| 73110 | <1% | 1,248 | $203K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,192 | $200K |
| 73030 | <1% | 1,635 | $199K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,645 | $193K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,836 | $186K |
| 73610 | <1% | 1,526 | $185K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 353 | $177K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,459 | $172K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 956 | $163K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 825 | $160K |
| 96376 | <1% | 1,977 | $159K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,286 | $159K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,162 | $158K |
| 82077 | <1% | 1,781 | $143K | |
| 83690 | <1% | 4,027 | $141K | |
| 84484 | <1% | 4,483 | $136K | |
| 73130 | <1% | 814 | $131K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,907 | $131K |
| 83605 | <1% | 3,168 | $130K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,413 | $123K |
| 87631 | <1% | 1,457 | $122K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,067 | $121K |
| 80050 | General health panel | <1% | 1,333 | $118K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 69 | $115K |
| 87040 | <1% | 3,011 | $110K | |
| 86140 | <1% | 3,673 | $108K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,241 | $106K |
| 80061 | Lipid panel | <1% | 3,879 | $106K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,211 | $104K |
| 76801 | <1% | 318 | $104K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,645 | $102K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,687 | $99K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,604 | $98K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,537 | $98K |
| 72100 | <1% | 695 | $98K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,707 | $98K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,320 | $96K |
| 73562 | <1% | 676 | $95K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 673 | $89K |
| 85027 | <1% | 3,634 | $89K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,539 | $84K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 275 | $78K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,382 | $73K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,086 | $68K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,181 | $68K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,757 | $67K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,977 | $64K |
| 76830 | Ultrasound, transvaginal | <1% | 206 | $63K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,340 | $63K |
| 80306 | <1% | 4,029 | $61K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,197 | $59K |
| 87186 | <1% | 851 | $58K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 235 | $57K |
| 81001 | <1% | 7,954 | $57K | |
| 86803 | <1% | 1,469 | $56K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 71 | $56K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,887 | $55K |
| 83735 | <1% | 3,718 | $55K | |
| 82962 | <1% | 3,138 | $54K | |
| 81025 | <1% | 2,855 | $52K | |
| 83880 | <1% | 1,530 | $52K | |
| 84145 | <1% | 1,071 | $51K | |
| 87081 | <1% | 1,187 | $49K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,443 | $48K |
| 87634 | <1% | 325 | $48K | |
| 80143 | <1% | 744 | $47K | |
| 97161 | <1% | 827 | $47K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 62 | $46K |
| 80179 | <1% | 691 | $44K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 373 | $44K |
| 87340 | <1% | 1,189 | $44K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 599 | $42K |
| 97162 | <1% | 799 | $42K | |
| 84439 | <1% | 1,851 | $41K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,478 | $41K |
| 94729 | <1% | 331 | $39K | |
| 86780 | <1% | 1,088 | $38K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 529 | $37K |
| 73502 | <1% | 369 | $35K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 283 | $34K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,079 | $33K |
| 86850 | <1% | 1,561 | $32K | |
| 87077 | <1% | 1,040 | $32K | |
| 81003 | <1% | 3,355 | $32K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 36 | $30K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,739 | $29K |
| 85379 | <1% | 677 | $29K | |
| 94726 | <1% | 303 | $29K | |
| 87070 | <1% | 789 | $28K | |
| 82570 | <1% | 1,445 | $28K | |
| G0378 | Hospital observation service, per hour | <1% | 125 | $27K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 66 | $27K |
| 82043 | <1% | 707 | $25K | |
| 82805 | <1% | 347 | $24K | |
| 85610 | <1% | 2,943 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 955 | $20K |
| 73564 | <1% | 127 | $19K | |
| 97035 | <1% | 953 | $19K | |
| 86762 | <1% | 548 | $18K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 809 | $18K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 761 | $16K |
| 82728 | <1% | 381 | $15K | |
| 87205 | <1% | 1,027 | $15K | |
| 90715 | <1% | 105 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 552 | $13K |
| 72040 | <1% | 106 | $13K | |
| 73140 | <1% | 145 | $13K | |
| 82607 | <1% | 608 | $12K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 543 | $12K |
| 83550 | <1% | 255 | $12K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 400 | $11K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 54 | $10K |
| 85652 | <1% | 2,134 | $10K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 280 | $10K |
| 87210 | <1% | 767 | $10K | |
| 94060 | <1% | 50 | $10K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 77 | $10K |
| 84702 | <1% | 271 | $10K | |
| 87075 | <1% | 401 | $9K | |
| 86901 | <1% | 784 | $9K | |
| 70496 | <1% | 12 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,370 | $9K |
| 83540 | <1% | 438 | $9K | |
| 71250 | <1% | 25 | $9K | |
| 76642 | <1% | 101 | $9K | |
| 95806 | <1% | 51 | $9K | |
| 86900 | <1% | 770 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 107 | $8K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 138 | $8K |
| 76641 | <1% | 134 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 40 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 266 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 296 | $6K |
| 87641 | <1% | 129 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 225 | $5K |
| 88142 | <1% | 274 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 81 | $5K |
| 97113 | <1% | 61 | $4K | |
| 85730 | <1% | 196 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 128 | $4K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 182 | $4K |
| 84403 | <1% | 54 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 126 | $3K |
| 96367 | <1% | 77 | $3K | |
| 87806 | <1% | 486 | $3K | |
| 87147 | <1% | 158 | $3K | |
| 72110 | <1% | 13 | $3K | |
| 71271 | <1% | 39 | $2K | |
| 87088 | <1% | 137 | $2K | |
| 59025 | Fetal non-stress test | <1% | 30 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 150 | $2K |
| 93017 | <1% | 12 | $2K | |
| 85018 | <1% | 415 | $2K | |
| 82550 | <1% | 177 | $2K | |
| 82951 | <1% | 36 | $2K | |
| 84156 | <1% | 76 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $1K |
| 36416 | <1% | 551 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 73080 | <1% | 13 | $1K | |
| 87400 | <1% | 101 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 84 | $1K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 62 | $1K |
| 82626 | <1% | 15 | $1K | |
| 86704 | <1% | 26 | $1K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 42 | $982.26 |
| 86038 | <1% | 26 | $932.21 | |
| 84481 | <1% | 13 | $927.59 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 16 | $850.01 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $764.34 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 26 | $739.52 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 43 | $700.05 |
| J1815 | Injection, insulin, per 5 units | <1% | 18 | $668.88 |
| 12001 | <1% | 15 | $665.30 | |
| 81015 | <1% | 133 | $662.48 | |
| 84100 | <1% | 154 | $588.58 | |
| 82746 | <1% | 14 | $504.11 | |
| 82950 | <1% | 57 | $494.42 | |
| 85014 | <1% | 101 | $476.45 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 38 | $473.53 |
| 85651 | <1% | 95 | $422.70 | |
| 86708 | <1% | 12 | $373.62 | |
| 87430 | <1% | 15 | $356.64 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $354.87 |
| 94760 | <1% | 15 | $317.79 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 13 | $295.38 |
| 84550 | <1% | 55 | $210.19 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 13 | $170.17 |
| 84460 | <1% | 28 | $96.21 | |
| 87176 | <1% | 12 | $68.35 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $31.39 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 46 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 45 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,800 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECREATRY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.